ramipril and Tuberculosis--Pulmonary

ramipril has been researched along with Tuberculosis--Pulmonary* in 3 studies

Trials

1 trial(s) available for ramipril and Tuberculosis--Pulmonary

ArticleYear
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].
    Problemy tuberkuleza, 1999, Issue:2

    A total of 108 patients with heart failure-complicated disseminated pulmonary tuberculosis were followed up. Fifty eight patients received combined therapy including the angiotensin-converting enzyme inhibitor ramipril in a daily dose of 0.25-0.50 mg for 1.5-2 months. Fifty ramipril-untreated patients comprised a control group. Examinations revealed the benefits of the agent in decompensatory chronic cor pulmonale as improved right ventricular systolic and diastolic functions and health in the patients.

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Pulmonary Heart Disease; Ramipril; Time Factors; Tuberculosis, Pulmonary

1999

Other Studies

2 other study(ies) available for ramipril and Tuberculosis--Pulmonary

ArticleYear
[Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].
    Problemy tuberkuleza, 2001, Issue:5

    The renin-angiotension-aldosterone system (RAAS) was studied in 93 patients with pulmonary tuberculosis complicated by chronic heart failure (CHF). Radioimmunoassay was used to determine plasma renin activity (PRA) and serum angiotensin I and aldesterone levels. There was higher RAAS activity, as shown by elevated PRA. RAAS activity decreased during CHF treatment with angiotension-converting enzyme inhibitors (captopril, ramipril, prestarium) and an angiotensin II-receptor blocker (cosaar), which is indicative of the efficiency of CHF treatment.

    Topics: Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Heart Failure; Humans; Radioimmunoassay; Ramipril; Renin; Renin-Angiotensin System; Tuberculosis, Pulmonary

2001
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].
    Problemy tuberkuleza, 2001, Issue:8

    Two and thirty four patients with pulmonary tuberculosis complicated with chronic heart failure (CHF) were examined to study life quality (LQ) and its changes due to hemodynamic correction. LQ was assessed by the Minnesota Life Heart Failure Quality questionnaire filled in by patients before and after treatment of CHF with angiotensin-converting enzyme inhibitors (captopril, ramipril, prestarium) and an angiotensin II-receptor blocker (cosaar) given for 1.5-2 months during chemotherapy for tuberculosis. In patients with pulmonary tuberculosis complicated by CHF, LQ was found to be related to the degree of hemodynamic disorders and to significantly improves with complex treatment of a tuberculous process and with correction of hemodynamic disorders.

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Emotions; Heart Failure; Hemodynamics; Humans; Perindopril; Pulmonary Heart Disease; Quality of Life; Ramipril; Socioeconomic Factors; Surveys and Questionnaires; Tuberculosis, Pulmonary

2001